- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of January 20
The Center for Biosimilars® recaps the top stories for the week of January 20, 2020.
Hi, I’m Gianna Melillo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 20, 2020
Number 5: Celltrion announces that it plans to launch 10 biosimilars over the next decade and will also open a large biologics manufacturing plant in China.
Number 4: A healthcare executive writes that providers should be able to help their patients reduce their out-of-pockets costs while providing the highest-quality care available through oncology biosimilars.
Number 3: Alvotech and JAMP Pharma announce a partnership to commercialize 5 biosimilars in the Canadian market.
Number 2: Gilead Science’s new chairman and chief executive officer outlines a growth plan at the J.P. Morgan Healthcare Conference.
Number 1: Teva Pharmaceuticals touts the launch of its biosimilar rituximab, Truxima, as evidence that it knows how to navigate the US pharmaceutical system.
To read all of these articles and more, visit centerforbiosimilars.com.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
